METHYLPREDNISOLONE SODIUM SUCCINATE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Methylprednisolone sodium succinate is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; it also decreases cytokine production and immune cell activity.
| Metabolism | Hepatic metabolism primarily via CYP3A4; methylprednisolone is metabolized to inactive metabolites that are excreted in urine. |
| Excretion | Renal: ~75% as metabolites (20-30% unchanged); Biliary/Fecal: minor (<10%) |
| Half-life | Terminal elimination half-life: 2.5-3.5 hours (plasma); biological half-life: 12-36 hours (based on pharmacodynamic effects due to intracellular receptor binding and gene regulation) |
| Protein binding | 68-77% bound to albumin and corticosteroid-binding globulin (CBG/transcortin) |
| Volume of Distribution | 0.7-1.5 L/kg (indicates wide distribution into tissues; crosses placenta and enters breast milk) |
| Bioavailability | Oral: 80-90% (varies with formulation); IM: 100% (prodrug converted rapidly); IV: 100% |
| Onset of Action | IV: 1-2 hours (peak effect in 4-8 hours); IM: 4-8 hours; Oral: 3-6 hours |
| Duration of Action | IV: 12-36 hours (duration of adrenal suppression and anti-inflammatory effect); IM: 4-8 days (depot effect); Oral: 12-36 hours |
Intravenous (IV) or intramuscular (IM) injection: 10-40 mg initially, then 10-40 mg every 6-12 hours. For pulse therapy: 1 g IV over 30 minutes daily for 3-5 days.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution and monitor for fluid retention; no specific dose adjustment recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or use with caution. Child-Pugh C: Avoid use or use lowest effective dose with close monitoring. |
| Pediatric use | IV/IM: 0.5-1.7 mg/kg/day divided every 6-12 hours. For pulse therapy: 15-30 mg/kg IV over 30 minutes daily for 3 days, maximum 1 g/day. |
| Geriatric use | Start at lower end of dosing range (e.g., 10 mg) due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. Monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Breastfeeding | Enters breast milk in low levels (M/P ratio ~0.3-0.4). Generally compatible; monitor infant for growth and development. No known adverse effects at therapeutic maternal doses. |
| Teratogenic Risk | First trimester: Cleft palate risk increased (OR 1.3-3.4) with systemic use. Second/third trimesters: Fetal growth restriction, adrenal suppression, preterm birth risk. Avoid high doses. Use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
None.
| Common Effects | Nausea Taste change Vomiting Diarrhea Constipation Cough Dizziness Weakness Headache Cold extremities Slow heart rate Numbness of extremity Increased potassium level in blood Decreased blood pressure |
| Serious Effects |
["Hypersensitivity to methylprednisolone or any component","Systemic fungal infections","Intrathecal route of administration (contraindicated)","Use in patients with idiopathic thrombocytopenic purpura (if given intramuscularly)","Concurrent live or live-attenuated vaccine administration (during immunosuppressive doses)"]
| Precautions | ["Increased risk of infections and masking of signs of infection","Adrenal suppression and insufficiency upon withdrawal, especially after prolonged therapy","Cushing's syndrome, hyperglycemia, diabetes mellitus","Osteoporosis and increased fracture risk","Gastrointestinal perforation, peptic ulcer, pancreatitis","Behavioral and mood disturbances (e.g., euphoria, insomnia, psychosis)","Increased intracranial pressure and pseudotumor cerebri","Ocular effects: cataracts, glaucoma, central serous chorioretinopathy","Cardiovascular: hypertension, thromboembolism, myocardial rupture in post-MI patients","Prolonged use may impair growth in children","Live or live-attenuated vaccines are contraindicated during immunosuppressive doses"] |
Loading safety data…
| Fetal Monitoring | Maternal: Blood glucose, blood pressure, electrolyte levels, signs of infection. Fetal: Ultrasound for growth (if prolonged use), neonate monitoring for adrenal insufficiency if maternal use in late pregnancy. |
| Fertility Effects | May impair ovulation (suppression of gonadotropins). Reversible upon discontinuation. Use may delay conception. No permanent effects. |